Ensysce Q2 Loss Widens to $2.6M, But $31M Cash Boost Extends Runway to 2027
ENSC sits 49% above its 52-week low of $0.23 on light trading volume (0.2× avg).
Summary
Ensysce reported a Q2 net loss of $2.60 million ($0.20 per share), wider than the prior year on higher R&D spending for PF614 and lower federal grant funding. The loss is narrower than Q1's $3.60 million, but the company remains unprofitable. Post-quarter, the Cy Biopharma acquisition and related financings added about $31 million in cash, extending the runway into late 2027 (or 2028 if milestones are met). Management plans to advance CY200 through Phase 2 and prepare for registrational development. This follows the strategic alternatives review announced in May and the Nasdaq delisting notices, but the new cash infusion and pipeline pivot provide a clearer path forward. The stock trades near $0.34, far below the $8.25 median analyst target, reflecting ongoing dilution and execution risk.
At the time of this announcement, ENSC was trading at $0.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.4M. The 52-week trading range was $0.23 to $2.75. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.